I apologize for the lack of posts but I just returned from Virginia where I served as an ad hoc reviewer for U.S. Army Medical Research and Materiel Command (USAMRMC) Prostate Cancer Research Program (PCRP) aka the Congressionally Directed medical Research Program. We spent two very intensive days reviewing prostate cancer research grant applications from [...]
Written by our own Richard Wassersug appearing in UroToday.com BERKELEY, CA (UroToday.com) – Much has happened with the use of androgen deprivation to treat prostate cancer (PCa) patients since Charles Huggins first castrated a patient in order to alleviate the symptoms of advanced PCa. Back then, patients were generally elderly and symptomatic with either urethral [...]
We are finding that there are many different types of prostate cancer, all of them are actually different diseases. At Memorial Sloane Kettering Hospital, New York City, they recently announced that, based on genetic analysis, they have identified 23 different types of prostate cancer. One of these cancer types is neuroendocrine prostate cancer which is [...]
November 21 is our country’s first annual Men’s Health Night. We’re asking every home to light a blue bulb that night, as a way to think about ourselves and the men we love, our sons, boyfriends, Dad’s, Uncles, Granddads, brothers, friends, partners, and husbands. One blue light bulb, one night a year, showing we care [...]
— A New Trial Marks Expanded Phase 3 Development of MDV3100 into Earlier-Stage Disease — Medivation, Inc. and Astellas Pharma Inc. today announced the launch of a second Phase 3 clinical trial of their investigational drug MDV3100. This trial marks the expansion of the Phase 3 development of their novel, triple-acting oral androgen receptor antagonist [...]